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Abstract Stimulation of pheochromocytoma PC12 cells by
cAMP-elevating agents caused the induction of the immediate
early gene 3CH134, which encodes MAP kinase phosphatase-1
(MKP-1). Forskolin was as potent as serum in stimulating MKP-
1 gene expression, whereas dibutyryl-cAMP and neuropeptide
PACAP were less effective. Induction of the MKP-1 gene was
accompanied by neo-synthesis of MKP-1 protein. MAP kinase
activation was not involved in the cAMP-induced MKP-1 gene
expression. The MAP kinase inactivation, that would result from
MKP-1 induction in response to increased intracellular cAMP
level, contributes to explain how hormones or neurotransmitters
signaling through cAMP influence cell growth and differentia-
tion. ß 2000 Federation of European Biochemical Societies.
Published by Elsevier Science B.V. All rights reserved.
Key words: Cyclic AMP; Forskolin; Immediate early gene;
Mitogen-activated protein kinase phosphatase;
Pituitary adenylyl cyclase-activating polypeptide; PC12 cell
1. Introduction
Mitogen-activated protein (MAP) kinases mediate multiple
pathways regulating cell growth and di¡erentiation (reviewed
in [1,2]). In neuronal cells, MAP kinase activity mediates the
actions of growth factors like EGF that stimulate cell prolif-
eration, and factors like NGF that maintain neuronal survival
and di¡erentiation. Activation of MAP kinase involves phos-
phorylation on threonine and tyrosine residues in a TxY mo-
tif, that is achieved by a sequential cascade of cytoplasmic
protein kinases. Three types of MAP kinases have been de-
scribed, depending their mode of activation and the nature of
the x amino-acid of the TxY motif. The archetypal MAP ki-
nases called extracellular signal-regulated kinases (ERK),
ERK1 and ERK2, possess a TEY motif and are activated
by the tumor promoter 12-O-tetradecanoyl-phorbol-13-ace-
tate (TPA) and by mitogens like EGF. A second MAP kinase
family comprises c-Jun N-terminal kinases (JNK) that are
activated through phosphorylation on a TPY motif [3]. The
third family consists of p38 MAPKs, that are activated
through phosphorylation on a TGY motif [4]. JNKs and
p38 kinases are activated by cellular stresses such as heat
shock or UV irradiation, and by proin£ammatory cytokines
[2].
Activated MAP kinases of the TEY family have been re-
ported to be speci¢cally dephosphorylated on both T and Y
residues by a dual speci¢c protein phosphatase, MAP kinase
phosphatase-1 (MKP-1) [5]. This phosphatase was identi¢ed
as the product of the immediate early gene 3CH134 [6]. The
importance of this dual protein phosphatase in cell biology is
emphasized by the fact that overexpression of MKP-1 has
been shown to block DNA synthesis and to slow cell division
[7^9]. The MAP kinase phosphatase family is rapidly expand-
ing (reviewed in [10^12]). It includes hVH-2, also cloned as
MKP-2 or TYP-1, as well as hVH-3, hVH-5 and MKP-5, all
encoded by immediate early genes. Whereas most of these
phosphatases are nuclear proteins, two members of this sub-
class, MKP-3 (also known as PYST1 or hVH-6) and MKP-4
are localized primarily within the cytosol.
The mechanisms by which MKP-1 mRNA is synthesized in
response to extracellular stimuli is presently a matter of con-
troversy. An early report showed that stimulation of JNK-
but not of ERK-induced MKP-1 gene expression in ¢bro-
blasts, suggesting that activation of JNK leads to inactivation
of ERK as a result of MKP-1 neo-synthesis [13]. In fact,
various reports indicate that transcriptional activation of
MKP-1 takes place through mechanisms involving one or
several MAP kinases [10,12,14,15]. Other reports however
suggest that this phosphatase can be induced by calcium
[16], phosphatidylinositol 3-kinase [17,18], protein kinase C
[19] or arachidonic acid [20]. We report here MKP-1 early
gene induction in response to cAMP-elevating agents in
PC12 cells, without stimulation of MAP kinases.
2. Materials and methods
2.1. Measurement of DNA synthesis
Rat pheochromocytoma PC12 cells were cultured as described [21].
They were serum-starved for 15 h and then treated with the various
agents together with 10 WM bromodeoxyuridine (BrdU). After 20 h of
BrdU incorporation, cells were ¢xed with 4% paraformaldehyde and
permeabilized with 0.2% Triton X-100. Cells were incubated for 2 h
with a monoclonal anti-BrdU antibody (Janssen Biochimica) at a 1:50
dilution in PBS, 3% bovine serum albumin and after extensive washes
in PBS, they were further incubated for 1 h with peroxidase-coupled
anti-mouse IgG (Dako) at a 1:100 dilution in PBS/bovine serum al-
bumin. Peroxidase activity was revealed with chloronaphtol.
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2.2. Northern blot and Western blot analysis
Total RNA was isolated from PC12 cells by the guanidinium iso-
thiocyanate method [22], separated by electrophoresis and blotted
onto Hybond N membranes (Amersham). Speci¢c MKP-1 mRNA
was detected as described previously [21] using a 32P-labeled cDNA
probe [5]. For quantitative analysis, densitometry was performed on
autoradiograms with an image analyzer. MKP-1 protein was detected
by Western blots performed as described [21], using anti-MKP-1 anti-
body (Santa Cruz Biotech., Santa Cruz, CA, USA).
2.3. JNK assay
Serum-starved PC12 cells were stimulated with various agents and
lysed in 0.5 ml of lysis bu¡er (10 mM Tris^HCl bu¡er, pH 7.4, con-
taining 150 mM NaCl, 1% Triton X-100, 1 mM EDTA, 1 mM
EGTA, 0.2 mM sodium vanadate, 0.2 mM phenylmethylsulfonyl £u-
oride and 0.5% NP-40) for 30 min at 4‡C. The lysates were incubated
for 2 h at 4‡C with 1 Wg of anti-JNK2 (Santa Cruz Biotech., USA)
and immunoprecipitation was accomplished by shaking for 1 h at 4‡C
with 50 Wl of a 10% protein A suspension (Pansorbin). After extensive
washing, JNK activity was assayed in the resuspended immunoprecip-
itation pellet. 30 Wg protein were incubated at 30‡C for 30 min in 40 Wl
total volume of 25 mM HEPES bu¡er, pH 7.5, containing 10 mM
magnesium acetate, [Q-32P]ATP (50 WM; 2 WCi), and 1 Wg of gluta-
thione S-transferase^c-Jun(1-79) (GST^c-Jun) fusion protein (Strata-
gene, USA). After heating to 95‡C for 5 min, the samples were ana-
lyzed by SDS(10%)^PAGE.
2.4. In vivo MAP kinase activation
MAP kinase activation was assayed in vivo by following Elk-1
phosphorylation using the PathDetect reporting system (Stratagene).
Cells were transfected with the several plasmids using the polyethyle-
nimine technique [23]. The cells were then incubated for 16 h, washed
and after another 24 h, they were treated with the various agents for
6 h. Luciferase was then extracted and its activity assayed by mixing
20 Wl of cell extract with 100 Wl of a reaction mixture containing
40 mM tricine (pH 7.8), 0.5 mM ATP, 0.5 mM EDTA, 10 mM
MgSO4, 10 mM dithiothreitol, 0.5 mM coenzyme A and 0.5 mM
luciferin, and the emitted light was measured.
3. Results
3.1. Induction of the MKP-1 gene by cAMP elevating agents
The e¡ect of various agents on MKP-1 gene transcription
was examined in serum-starved PC12 pheochromocytoma
cells. Fig. 1A shows that addition of 20% serum highly in-
duced gene induction, whereas NGF produced only a modest
induction. Quantitative analysis indicated that NGF produced
approximately 15% of the e¡ect achieved by serum. Surpris-
ingly, 10 WM of the adenylyl cyclase activator forskolin was
found as potent as serum in inducing MKP-1 gene transcrip-
tion. MKP-1 mRNA expression was already induced after
15 min incubation, and was highly enhanced at 30 min, in agree-
ment with kinetics described for the expression of an imme-
diate early gene. Increasing intracellular Ca2 concentration
by adding the Ca2 ionophore A23187 (Fig. 1B) resulted in an
induction of the MKP-1 gene transcription to a level corre-
sponding to 15% of the induction achieved by serum. An even
weaker induction was caused by TPA (4% of the serum e¡ect).
Fig. 2A presents the dose-dependency of forskolin and di-
butyryl cAMP (Bt2cAMP) in inducing MKP-1 gene transcrip-
tion. Forskolin provoked gene induction at a concentration as
low as 0.1 WM. Treatment of PC12 cells with 1 mM of the
membrane permeant cAMP analogue Bt2cAMP for 30 min
resulted also in a signi¢cant increase in MKP-1 mRNA,
reaching 34% of the induction achieved by 1 WM forskolin
(Fig. 2A). The addition of the selective cAMP-dependent pro-
tein kinase (PKA) inhibitor 8-bromoadenosine 3P,5P-mono-
phosphorothioate (Rp-8-Br-cAMPS, Biolog, Germany) at
0.2 mM partially abolished the MKP-1 gene transcription
induced by the cAMP-elevating agents (Fig. 2B). It inhibited
the e¡ect of forskolin by 54% and that of Bt2cAMP by 80%.
Similar results were obtained with the less selective PKA in-
hibitor H89 (data not shown). These results show that for-
skolin and Bt2cAMP produced their e¡ect on gene transcrip-
tion probably through the activation of PKA.
We next veri¢ed that the MKP-1 gene could also be in-
duced by hormones known to use cAMP as a second messen-
Fig. 1. Northern blot analysis of immediate early gene MKP-1 in-
duction by various agents in PC12 cells. Total RNA (20 Wg/lane)
was extracted from serum-starved PC12 cells incubated with (A)
10 WM forskolin (Fsk), 20% fetal calf serum, or 50 ng/ml NGF, and
(B) 100 ng/ml TPA, or 10 WM of the Ca2 ionophore A23187. The
right side arrow indicates hybridization signal of MKP-1. The lower
panel presents the 28S rRNA revealed by methylene-blue staining of
the blot, showing equal loading of RNA. The ¢gures are representa-
tive of three experiments.
Fig. 2. E¡ect of various concentrations of forskolin and Bt2cAMP
(A), and of PKA inhibitor Rp-8-Br-cAMPS (B) on MKP-1 mRNA
expression. A: PC12 cells were treated with the indicated concentra-
tion of the agents for 30 min. B: Rp-8-Br-cAMPS (0.2 mM) was
added 4 h before 1 WM forskolin (Fsk) or 1 mM Bt2cAMP. Total
RNA was analyzed as described in Section 2 and Fig. 1.
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ger. Addition of the neuropeptide pituitary adenylyl cyclase-
activating polypeptide (PACAP27) to PC12 cells resulted in
an increase in MKP-1 mRNA expression. However, 1 nM
PACAP27 produced an induction that corresponded only to
18% of that produced by 1 WM forskolin (Fig. 3A). Fig. 3B
shows that PACAP27 and PACAP38 produced a very similar
induction of the MKP-1 gene.
3.2. Synthesis of MKP-1 protein by forskolin
In order to verify that MKP-1 gene induction resulted in
the neo-synthesis of the corresponding protein, we measured
the induction of the MKP-1 protein. Fig. 4 shows that both
forskolin and Bt2cAMP induced MKP-1 synthesis, as detected
by the band appearing at Mr 40 000, in agreement with the
apparent Mr reported in [7]. The intensity of the band induced
by forskolin was higher than that induced by serum.
3.3. Cyclic AMP-elevating agents failed to activate MAP
kinases
We investigated whether cAMP-elevating agents were pro-
moting MKP-1 gene expression through the activation of
MAP kinases. Fig. 5A shows that PD98059, a speci¢c inhib-
itor of the kinase upstream to ERK1 and ERK2, did not
inhibit the forskolin-induced MKP-1 induction. Also, the
p38 kinase inhibitor SB203580 failed to abolish the forsko-
lin-induced MKP-1 induction (Fig. 5B). Moreover, neither
forskolin nor Bt2cAMP were found to stimulate JNK activity
in whole cell extracts, whereas JNK enzymatic activity was
Fig. 3. E¡ect of PACAP peptides on MKP-1 gene induction. Cells
were treated for 30 min (A) with 10 WM forskolin (Fsk), or with
the indicated concentration of PACAP27, and (B) with 1 nM of
PACAP27 or PACAP38. Total RNA was analyzed as described in
Section 2 and Fig. 1.
Fig. 4. Western blot analysis showing MKP-1 protein synthesis by
cAMP-elevating agents. PC12 cells were incubated for 1 h with 20%
fetal calf serum, 10 WM forskolin (Fsk), or 1 mM Bt2cAMP. The
amount of protein loaded in each lane was normalized, using the
Bradford reagent technique. Immunoreactive signals were visualized
by chemiluminescence. Apparent molecular weights of marker pro-
teins are indicated at the left. The ¢gure is representative of two ex-
periments. Arrow indicates MKP-1 protein.
Fig. 5. E¡ect of MAP kinase inhibitors on forskolin-induced MKP-
1 gene expression. Cells were treated for 30 min (A) with 1 WM for-
skolin (Fsk) and 20 WM PD98059, or (B) with 1 WM Fsk and 1 or
10 WM SB203580. PD98059 and SB203580 were added 30 and 60
min before forskolin, respectively. Total RNA was analyzed as de-
scribed in Section 2 and Fig. 1. The ¢gure is representative of three
experiments.
Fig. 6. E¡ect of serum and cAMP-elevating agents on JNK activity.
PC12 cells were incubated for 15 min with 10 WM forskolin (Fsk),
1 mM Bt2cAMP, 1 nM PACAP27, 20% fetal calf serum, or 0.5 M
sorbitol. Whole cell extracts were prepared as described and JNK
assayed for its ability to phosphorylate GST-c-Jun. The right lane
(JNK) shows the phosphorylation of GST-c-Jun by puri¢ed re-
combinant JNK. The ¢gure is representative of three separate obser-
vations.
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strongly activated by osmotic stress induced by sorbitol (Fig.
6). Very similar results were obtained when JNK activity was
measured in the complex obtained after immunoprecipitation
of cell lysate by an antibody reacting with both JNK1 and
JNK2 (data not shown). To further investigate whether MAP
kinases participated in the induction of MKP-1 by cAMP, we
examined the in vivo Elk-1 phosphorylation in response to
cAMP-elevating agents, since Elk-1 is known to be a common
substrate of the three MAP kinase families. Fig. 7 shows Elk-1
phosphorylation revealed by the luciferase activity expressed
from a reporter vector under the control of a fusion activator
protein containing the GAL4 DNA binding domain and the
Elk-1 activation domain. Serum growth factors produced a
tremendous phosphorylation of Elk-1, whereas no such in-
crease was observed in response to forskolin or Bt2cAMP,
con¢rming that none of the MAP kinase pathways was stimu-
lated in response to cAMP-elevating agents. The participation
of phosphatidyl inositol 3-kinase activation can also be ruled
out since its inhibitor wortmannin did not signi¢cantly modify
the cAMP-induced MKP-1 gene transcription (data not
shown).
3.4. MKP-1 induction correlates with the reduction in the
number of cells entering S phase
PKA-mediated inhibition of cell division is commonly re-
vealed by blockade of the passage of growth factor-stimulated
cells into S phase of the cell cycle. To determine whether this
blockade correlates with cAMP-dependent MKP-1 induction,
we examined the kinetics of cell cycle re-entry (Table 1). Stim-
ulation of quiescent cells with serum resulted in the re-entry of
97% of the cell population into S phase of the cell cycle.
Forskolin, which failed to stimulate entry into S phase on
its own, attenuated serum-mediated increases in BrdU incor-
poration by approximately 44%. Forskolin added 2 h before
serum, thus inducing expression of MKP-1 protein, inhibited
the serum-mediated BrdU incorporation to about 90%.
4. Discussion
We report here the induction of the early gene 3CH134,
encoding the MAP kinase phosphatase MKP-1, in response
to various extracellular stimuli in serum-starved PC12 cells.
Highest MKP-1 mRNA induction was obtained with serum,
in agreement with an early study in which the gene was iden-
ti¢ed [6]. We also found that MKP-1 gene and protein were
very strongly induced by the cAMP-elevating agents forskolin
and Bt2cAMP. This ¢nding was con¢rmed by using the neu-
ropeptides PACAP. Receptors for PACAP27 and PACAP38
have been shown to be present on PC12 cells, coupled to
adenylyl cyclase, and to both adenylyl cyclase and phospho-
lipase C, respectively [24]. Both peptides produced a very sim-
ilar e¡ect on MKP-1 gene induction, strongly suggesting that
it is actually the cAMP increase that mediates their e¡ects on
MKP-1 gene transcription.
Since several studies show that MKP-1 gene transcription is
induced by MAP kinases [11,12], our ¢nding raises the ques-
tion whether its induction by cAMP involved the activation of
one (or more) MAP kinase pathway(s). In fact, only ERK1
and ERK2 were shown to be activated by cAMP in PC12 cells
[25,26]. But we found that ERKs were not involved in the
mechanisms of MKP-1 induction since agents such as TPA
or NGF, which are well characterized for activating ERKs,
were very weak MKP-1 activators. Moreover, inhibition of
the ERK pathway by PD98059 did not reduce the forskolin-
stimulated MKP-1 expression. We also found no evidence in
the present study for JNK being activated by cAMP-elevating
agents, despite the fact that MKP-1 was reported to be
strongly induced by JNK activation [13]. Moreover, the os-
motic stress inducer sorbitol, which strongly stimulates JNK
enzymatic activity, was not found to induce MKP-1 gene tran-
scription (data not shown). Also, MKP-1 induction was not
abolished by the p38 kinase inhibitor SB203580. Finally,
cAMP-elevating agents were not found to phosphorylate
and activate in vivo Elk-1, a common substrate of the three
MAP kinase families. Together, our results indicate that in
PC12 cells none of the MAP kinase pathways was involved
in MKP-1 gene induction by cAMP. This was also the case
when MKP-1 was induced by arachidonic acid in vascular
smooth muscle cells [20], or by PKC activators in CCL39
Fig. 7. In vivo Elk-1 phosphorylation in response to serum and
cAMP-elevating agents. PC12 cells were transfected with 1 Wg pFR-
Luc reporter plasmid and 50 ng pFA-Elk fusion trans-activator
plasmid encoding the activation domain of Elk. At 40 h post-trans-
fection, cells were treated for 6 h with 20% fetal calf serum, 1 or 10
WM forskolin (Fsk) or 1 mM Bt2cAMP, and then collected for lucif-
erase assay. Bars represent the mean (arbitrary units) þ S.D. of
three experiments. Transfection with a plasmid constitutively ex-
pressing an upstream activator of JNK produced a luciferase activ-
ity of 470 arbitrary units.
Table 1
cAMP-elevating agents reduce the number of cells entering S phase
Treatment Cells incorporating BrdU (%)
Control 6.5
Serum 97.4
Forskolin 7.3
Forskolin+serum 54.3
Forskolin+serum 2 h later 10.2
PC12 cells (24-well plates) were rendered quiescent after 5 days in
culture by overnight serum removal. Following a 20-h stimulatory
period with 20% fetal calf serum or 10 WM forskolin in the presence
of 10 WM BrdU, the percentage of cells which had incorporated
BrdU were counted (at least 150 cells for each treatment). Data are
from a single experiment representative of three performed.
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¢broblasts [27]. Alternatively, PKA might induce MKP-1 gene
expression by activating a transcription factor through the
inhibition of its dephosphorylation, since PKA is known for
phosphorylating proteins of the I-1 family which, once phos-
phorylated, become strong inhibitors of Ser/Thr protein phos-
phatase type-1 (reviewed in [28]). Interestingly, the protein
phosphatase inhibitor okadaic acid was found to induce
MKP-1 gene transcription in PC12 cells [29].
Although in most cells cAMP is without e¡ect or inhibits
the growth factor-activated ERK pathway [30], there are con-
£icting reports on whether this is the case in PC12 cells
[31,32]. Stimulation of MAP kinase activity by cAMP was
actually reported in PC12, Swiss 3T3 and COS-7 cells. In
PC12 cells, a positive cAMP e¡ect on MAP kinase pathway
is accompanied by a marked increase in the number of neu-
rite-bearing cells [25,26]. It is di⁄cult to conciliate the present
data on cAMP-mediated MKP-1 induction with a role in
neurite outgrowth since (i) NGF was not found to activate
substantially MKP-1 gene transcription, (ii) MAP kinase ac-
tivation was not involved in the events leading to MKP-1
induction, and (iii) MKP-1 activation would result in even
lower MAP kinase activity. The MKP-1 activation in response
to the increased intracellular cAMP level reported here is
probably involved in the inhibition of PC12 cell proliferation,
since the e¡ect of cAMP in attenuating serum-mediated in-
creases in the number of cells that re-enter S phase was corre-
lated with MKP-1 expression. On the other hand, MKP-1
overexpression has already been shown to block DNA syn-
thesis and to inhibit cell division [7^9]. It appears that the
regulation of MKP-1 expression is achieved by complex mech-
anisms that are speci¢c to the cell type considered. These
mechanisms have to be established in order to fully compre-
hend the role of MKP-1 in cell biology.
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